

1 **Isolation thresholds for curbing SARS-CoV-2 resurgence**

2 Laith Yakob

3 Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London,
4 England, WC1E 7HT (laith.yakob@lshtm.ac.uk; +44(0)207 927 2684)

5

6

7 **Summary**

8 Self-instigated isolation is heavily relied on to curb SARS-CoV-2 transmission. Accounting for
9 uncertainty in the latent and prepatent periods, as well as the proportion of infections that remain
10 asymptomatic, the limits of this intervention at different phases of infection resurgence are
11 estimated. We show that by October 2020, SARS-CoV-2 transmission rates in England had already
12 begun exceeding levels that could be interrupted using this intervention alone, lending support to
13 the second national lockdown on November 5th 2020.

14

15 **Keywords**

16 Covid-19; mathematical model; quarantine; intervention

17

18

19

20

21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 A general population lockdown occurred in England on 23rd March 2020 to reduce SARS-CoV-2
23 transmission. This drastic intervention successfully inhibited disease spread by rapidly depleting the
24 opportunities for transmission events between infected and susceptible people remaining in general
25 circulation [1].

26 Subsequent to easing out of lockdown from July 4th 2020, infections resurged and England entered
27 its second national lockdown on November 5th 2020. The return of millions of (largely susceptible)
28 people to general circulation underlies the epidemic re-entering an exponential growth phase.
29 However, also culpable in the current public health emergency is the failure of interventions during
30 the period following lockdown's release.

31 Contact tracing endeavours in 2020 to reduce SARS-CoV-2 transmission have been ineffective in
32 England and so isolation has been primarily instigated by those responding to symptoms'
33 development in themselves or their close associations [2]. The mechanism by which this reactive
34 isolation operates is importantly distinct from pre-emptive mass quarantine (lockdown). Symptoms-
35 prompted, reactive isolation only applies to individuals who are infected (c.f. the total population),
36 and, more specifically, to those who register symptoms. Hence infectious individuals who have not
37 yet experienced symptoms, or who will never experience them, are missed.

38 The mathematical epidemiology of reactive isolation is fairly nascent yet critical in the context of the
39 current epidemic. Here, we generate estimates for reactive isolation thresholds that account for
40 uncertainties in the latent and pre-patent period of infection as well as in the proportion of infected
41 individuals that register and respond appropriately to symptoms.

42

43 *Mathematical derivation of reactive self-isolation*

44 Beginning with the simplest derivation for physical isolation: the pre-emptive quarantine threshold
45 proportion (Q) is $Q > (1 - (1/R))$ where ' R ' is the reproduction number [3]. For reactive isolation (Q^*),

46 this threshold is inflated to account for the leaked infections occurring because of the delay between
47 becoming infectious and first exhibiting symptoms: $Q^* > (1 - (1/R)) \times [1/(1 - ((p - l)/g))]$.
48 Respectively, p and l are the prepatent and latent period of infection (in days), and g is time until
49 recovery (12 days on average [4]). If symptoms typically develop at the same time as an individual
50 becomes infectious, the square-bracket component equals one and the original threshold (Q) is
51 regained. A further modification can be made to account for the proportion of infections that never
52 give rise to symptoms (denoted ' a '): $Q^{**} > (1/(1 - a)) \times (1 - (1/R)) \times [1/(1 - ((p - l)/g))]$. For example,
53 if half of infections remained asymptomatic, the proportion of symptomatic infections that need to
54 be isolated to achieve an equivalent impact must be doubled. As with those who never develop
55 symptoms, individuals who fail to respond appropriately to developing symptoms – early indication
56 is that this is not a negligible proportion [5] – will continue to contribute to transmission, so ' a ' could
57 be considered a composite of these two proportions.

58


59

60 *Accounting for uncertainty in parametrization*

61 The latent and prepatent periods are quite variable for COVID-19 patients. Instead of single point
62 estimates for these parameters, collated data form a distribution of reported times. The latent
63 period is drawn at random from a Weibull distribution and then subtracted from the random draw
64 from a second Weibull distribution depicting the range of reported prepatent periods. Fig 1A
65 illustrates these distributions as informed by the clinical and epidemiological literature [6-8]. Also
66 shown is the distribution of times between development of infectiousness and symptoms onset as
67 fitted to 10,000 random draws. The distributions of prepatent and latent periods overlap so to avoid
68 the possibility of symptoms developing prior to infectiousness, random draws whereby
69 infectiousness trailed the day of symptoms onset were removed and resampled. 10,000 random
70 draws were then made from this newly derived distribution of the delay between infectiousness and

71 symptoms, and the isolation threshold (Q^{**}) was estimated for a range of R values and a range of
72 asymptomatic proportions (Python code for this analysis is freely available on
73 <https://github.com/lwyakob/COVIDquarantine>).

74



75

76 **Figure 1. A) Dashed lines indicate distributions for the latent (blue, Weibull($\alpha=4$, $\beta=2$)) and**
77 **prepatent period (red, Weibull($\alpha=6$, $\beta=3$)) as derived from the COVID-19 literature [6-8]. The solid**
78 **line is the resulting distribution for the time difference between the two from which 10,000**
79 **random draws were made (inset). B) The isolation threshold (Q^*) as calculated for the 10,000**
80 **random draws along with the mean (white line) and 95% predictive interval (dashed lines). The**
81 **blue cross indicates the theoretical maximum R number for which reactive isolation may interrupt**
82 **transmission. C) The maximum asymptomatic proportion of COVID-19 infections that permits**
83 **transmission interruption by reactive isolation for a range of R values (the hatched curve is**
84 **calculated using the expression for Q^{**}). The red boxes illustrate estimates for the asymptomatic**
85 **proportion and the R for England as of October 2020 [9, 10].**

86

87 *Isolation thresholds accounting for uncertainty*

88 Fig 1B shows the mean isolation threshold required to control SARS-CoV-2 accounting for the range
89 of estimates for the prepatent and latent periods. The value for R is dynamic, varying according to
90 current intervention effectiveness and population-level susceptibility, so the isolation threshold is
91 shown for a range of plausible R values. The form of the relationship between Q^* and R shows an
92 isolation threshold that increases asymptotically with reproduction number. However, allowing for
93 uncertainty in prepatent and latent periods results in a wide 95% prediction interval. The
94 interpretation is that when accounting for both the uncertainty in estimating the population mean,
95 plus the random variation of the individual values, reactive isolation cannot interrupt transmission
96 (at least 95 times out of 100) if R already exceeds a value of ~ 1.7 (blue cross on Fig 1B marks the R
97 value whereby the isolation threshold proportion exceeds unity).

98 Reactive isolation is further limited when asymptomatic infections comprise a non-negligible
99 proportion (alternatively, when those exhibiting symptoms fail to isolate themselves to some
100 degree). Fig 1C shows the theoretical limits of the proportion of infections that can be asymptomatic
101 and yet SARS-CoV-2 transmission interrupted through isolating symptomatic individuals (using the
102 Q^{**} expression). Superimposed on this trade-off between the reproduction number and the
103 isolation threshold are estimates for R in England as of October 2020 [10], and the 95% confidence
104 and predictive intervals for the proportion of infections that remain asymptomatic as generated by a
105 living systematic review [9]. Respectively, by October 75% and 85% of these parameter spaces were
106 already beyond the level at which reactive isolation can be sufficient to interrupt transmission (i.e.,
107 these regions fall to the right of the hatched arc in Fig 1C meaning the isolation threshold proportion
108 exceeds unity).

109

110

111 *Limitations and future work*

112 One limitation of the current analysis is the consideration of transmission and control at the
113 population level rather than stratified by various risk factors. To address this, results were generated
114 for a full range of R values. It is important to note that stratification would impact the derivation of R
115 but not the population-level isolation thresholds calculated for a given R value [11]. Another
116 limitation is the implicit assumption that, in the absence of intervention, asymptotically infected
117 individuals contribute to onwards transmission as much as symptomatically infected individuals. It is
118 unclear how questionable this assumption is but clinical studies indicate that asymptomatic and
119 symptomatic individuals have similar viral loads [12]. Should evidence arise of their differential
120 contributions to transmission, the model and code associated with this study can be modified easily
121 to account for this feature.

122 Even during pre-emptive quarantine (i.e., lockdown) the formulae described here continue to apply
123 to those who remain in general circulation (e.g., essential personnel). Future work should look at
124 how isolation thresholds can be estimated to inform this intervention combination, among others.

125

126

127

128

129

130

131

132

133

134 References

- 135 (1) **Nightingale E, Brady OJ, Yakob L.** The importance of saturating density dependence for
136 predicting SARS-CoV-2 resurgence. *medRxiv* 2020: 2020.2008.2028.20183921.
- 137 (2) **Moon J, et al.** Optimising 'Test and Trace' Systems: Early lessons from a comparative analysis
138 of six countries. *SSRN* 2020: <http://dx.doi.org/10.2139/ssrn.3694441>.
- 139 (3) **Anderson RM, May RM.** *Infectious Diseases of Humans: Dynamics and Control*. Oxford: Oxford
140 University Press, 1991.
- 141 (4) **He X, et al.** Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature*
142 *Medicine* 2020; **26**(5): 672-675.
- 143 (5) **Smith LE, et al.** Factors associated with adherence to self-isolation and lockdown measures in
144 the UK: a cross-sectional survey. *Public Health* 2020; **187**: 41-52.
- 145 (6) **Nishiura H, Linton NM, Akhmetzhanov AR.** Serial interval of novel coronavirus (COVID-19)
146 infections. *International Journal of Infectious Diseases* 2020; **93**: 284-286.
- 147 (7) **Backer JA, Klinkenberg D, Wallinga J.** Incubation period of 2019 novel coronavirus (2019-
148 nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. *Eurosurveillance* 2020;
149 **25**(5): 2000062.
- 150 (8) **Kretzschmar ME, et al.** Impact of delays on effectiveness of contact tracing strategies for
151 COVID-19: a modelling study. *The Lancet Public Health* 2020; **5**(8): e452-e459.
- 152 (9) **Buitrago-Garcia D, et al.** Occurrence and transmission potential of asymptomatic and
153 presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLOS Medicine*
154 2020; **17**(9): e1003346.
- 155 (10) **Riley S, et al.** High prevalence of SARS-CoV-2 swab positivity and increasing R number in
156 England during October 2020: REACT-1 round 6 interim report. *medRxiv* 2020:
157 2020.2010.2030.20223123.
- 158 (11) **Fine P, Eames K, Heymann DL.** "Herd Immunity": A Rough Guide. *Clinical Infectious Diseases*
159 2011; **52**(7): 911-916.
- 160 (12) **Lee S, et al.** Clinical Course and Molecular Viral Shedding Among Asymptomatic and
161 Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic
162 of Korea. *JAMA Internal Medicine* 2020; **180**(11): 1447-1452.

163

164

165 **Data availability statement:** Data and model code are all available from
166 <https://github.com/lwyakob/COVIDquarantine>

167 **Financial support:** The author received no financial support for this work.

168 **Conflicts of interests:** None.

169

170